



LKT Laboratories, Inc.

ARV-825

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID A706840

CAS No. 1818885-28-7

Chemical Name 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-(2-(2-(2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-ylamino)ethoxy)ethoxy)ethoxy)ethoxy)

Synonym ARV825; SCHEMBL17162093; RWLOGRLTDKDANT-TYIYNAFKSA-N; BCP19950; CS-4776

Formula C₄₆H₄₇ClN₈O₉S

Formula Wt. 923.44

Melting Point


Purity ≥99%

Solubility DMSO (1 mg/mL), DMF (5 mg/mL).

Store Temp -20°C

Ship Temp Ambient

Description ARV-825 is a small-molecule degrader of BET proteins that has been shown to inhibit acute myeloid leukemia cell proliferation and induce apoptosis. It has also been demonstrated that ARV-825 may inhibit cell proliferation, induce apoptosis, and induce cell cycle arrest in vitro against a multiple myeloma cell line, and inhibit cell growth in vivo in a mouse xenograft.



Bulk quantities available upon request

Product ID	Size
A706840	1 mg
A706840	5 mg
A706840	25 mg

References Piya S, Mu H, Bhattacharya S, et al. BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment. *J Clin Invest.* 2019 Feb 21;130. pii:120654. PMID: 30829648.

Lim SL, Damernsawad A, Shyamsunder P, et al. Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations. *Haematologica.* 2019 Jan 3. pii:haematol.2018.201483. PMID: 30606790.

Saenz DT, Fiskus W, Qian Y, et al. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. *Leukemia.* 2017 Sep;31(9):1951-1961. PMID: 28042144.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.